Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease
Article first published online: 28 MAY 2013
© 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
International Journal of Rheumatic Diseases
Volume 16, Issue 4, pages 442–447, August 2013
How to Cite
Yanaba, K., Yoshizaki, A., Muroi, E., Ogawa, F., Shimizu, K. and Sato, S. (2013), Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. International Journal of Rheumatic Diseases, 16: 442–447. doi: 10.1111/1756-185X.12094
- Issue published online: 31 AUG 2013
- Article first published online: 28 MAY 2013
- Ministry of Health, Labor and Welfare of Japan
- interstitial lung disease;
- systemic sclerosis;
- vascular adhesion protein-1
To determine circulating soluble vascular adhesion protein-1 (sVAP-1) levels and their clinical associations in patients with systemic sclerosis (SSc).
Serum VAP-1 levels were examined by enzyme-linked immunosorbent assay in 71 SSc patients, 13 systemic lupus erythematosus patients and 50 healthy individuals.
Serum sVAP-1 levels were significantly elevated in SSc patients (617.2 ± 338.7 ng/mL) compared with healthy individuals (320.2 ± 144.2 ng/mL; P < 0.001) and patients with systemic lupus erythematosus (329.0 ± 176.1 ng/mL; P < 0.001). Among SSc patients, there were no differences in serum sVAP-1 levels between those with limited cutaneous SSc and those with diffuse cutaneous SSc. SSc patients with raised sVAP-1 levels had interstitial lung disease and decreased percent vital capacity less often than those with normal sVAP-1 levels. sVAP-1 levels were positively correlated with percent vital capacity in patients with SSc.
Serum sVAP-1 levels were increased in patients with SSc, and associated with a lower frequency and severity of interstitial lung disease in SSc, suggesting that sVAP-1 plays a role in the pathogenesis of interstitial lung disease in SSc.